Tonix Pharma Files 8-K on Dec 9, 2025
Ticker: TNXP · Form: 8-K · Filed: Dec 9, 2025 · CIK: 1430306
Sentiment: neutral
Topics: 8-K, corporate-events, financial-reporting
TL;DR
Tonix Pharma dropped an 8-K on 12/9/25 - check it for Reg FD, other events, and financials.
AI Summary
Tonix Pharmaceuticals Holding Corp. filed an 8-K on December 9, 2025, reporting on events including a Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company, formerly known as Tamandare Explorations Inc., is incorporated in Nevada and headquartered in Chatham, New Jersey.
Why It Matters
This filing provides an update on Tonix Pharmaceuticals' corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status and regulatory compliance.
Risk Assessment
Risk Level: low — This is a routine 8-K filing reporting on corporate events and financial statements, not indicating any immediate significant risks.
Key Players & Entities
- Tonix Pharmaceuticals Holding Corp. (company) — Registrant
- Tamandare Explorations Inc. (company) — Former company name
- December 9, 2025 (date) — Filing date and earliest event reported
- Nevada (jurisdiction) — State of incorporation
- Chatham, New Jersey (location) — Principal executive offices
FAQ
What specific events are being disclosed under Regulation FD?
The filing indicates a Regulation FD Disclosure, but the specific details of the disclosure are not provided in the provided text.
What are the 'Other Events' reported in this 8-K?
The filing lists 'Other Events' as an item, but the nature of these events is not detailed in the provided text.
When was Tonix Pharmaceuticals Holding Corp. formerly known as Tamandare Explorations Inc.?
The date of the name change from Tamandare Explorations Inc. to Tonix Pharmaceuticals Holding Corp. was March 20, 2008.
What is the business address and phone number for Tonix Pharmaceuticals Holding Corp.?
The business address is 26 Main Street, Suite 101, Chatham, New Jersey, 07928, and the telephone number is (862) 799-8599.
What is the SIC code for Tonix Pharmaceuticals Holding Corp.?
The Standard Industrial Classification (SIC) code for Tonix Pharmaceuticals Holding Corp. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 771 words · 3 min read · ~3 pages · Grade level 13 · Accepted 2025-12-09 07:33:55
Filing Documents
- tonix-8k_120925.htm (8-K) — 28KB
- ex99-01.htm (EX-99.1) — 42KB
- image_001.jpg (GRAPHIC) — 7KB
- 0001999371-25-019833.txt ( ) — 252KB
- tnxp-20251209.xsd (EX-101.SCH) — 3KB
- tnxp-20251209_lab.xml (EX-101.LAB) — 33KB
- tnxp-20251209_pre.xml (EX-101.PRE) — 22KB
- tonix-8k_120925_htm.xml (XML) — 3KB
01
Item 7.01 Regulation FD Disclosure. On December 9, 2025, Tonix Pharmaceuticals Holding Corp. (the "Company") announced the appointment of Irina Ishak as General Counsel, effective immediately. A copy of the press release which discusses this matter is furnished hereto as Exhibit 99.01, and incorporated herein by reference. The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.01 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Other Events
Item 8.01. Other Events. On December 9, 2025, the Company announced the appointment of Irina Ishak as General Counsel, effective immediately.
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the SEC. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibit No. Description. 99.01 104 Press Release of the Company, December 9, 2025 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. TONIX PHARMACEUTICALS HOLDING CORP. Date: December 9, 2025 By: /s/ Bradley Saenger Bradley Saenger Chief Financial Officer